Please login to the form below

Not currently logged in
Email:
Password:

antibiotic research

This page shows the latest antibiotic research news and features for those working in and with pharma, biotech and healthcare.

Sandoz to acquire GSK’s cephalosporin antibiotic brands for up to $500m

Sandoz to acquire GSK’s cephalosporin antibiotic brands for up to $500m

GSK still has some antibiotic assets, including its investigational drug gepotidacin which is being evaluated in phase 3 for the treatment of uncomplicated urinary tract infection (UT) and urogenital gonorrhoea. ... The pharma industry has refocused on

Latest news

More from news
Approximately 1 fully matching, plus 29 partially matching documents found.

Latest Intelligence

  • How COVID-19 is accelerating the threat of antimicrobial resistance How COVID-19 is accelerating the threat of antimicrobial resistance

    This included the Global Antibiotic Research and Development Partnership (GARDP) and the British Society for Antimicrobial Chemotherapy (BSAC). ... Other organisations across Europe also called on HCPs not to neglect antibiotic stewardship.

  • Combining therapies and combining research Combining therapies and combining research

    Thankfully research is very much alive among the more agile, super-specialist research organisations. ... Combination therapy. Antibiotic Combination Therapy was developed in 1952 for the treatment of tuberculosis.

  • Another lost decade for research? Another lost decade for research?

    In contrast to the antibiotic field, our research, found in our separate report, Microbial infection: Point-of-care diagnostics, into patent filings relating to POC diagnostics over the past five years ... In terms of research focus, the majority of

  • Curbing the rise of drug resistance Curbing the rise of drug resistance

    The KPMG report urges governments and global life sciences businesses to invest more in antibiotic research and development, yet, the recent acquisition of Cubist Pharmaceuticals by Merck &Co. ... The authors’ full report: The global economic impact of

  • The impending threat of antibiotic resistance The impending threat of antibiotic resistance

    Antibiotic Research UK is the BIA's charity of 2015, but what does it intend to do? ... Named Antibiotic Research UK (ANTRUK) the charity is the world's first dedicated to developing new antibiotics against antibiotic resistant infections.

More from intelligence
Approximately 1 fully matching, plus 4 partially matching documents found.

Latest appointments

  • Cubist picks Robert Perez as its new CEO Cubist picks Robert Perez as its new CEO

    With Bonney as CEO Cubist has emerged as one of the leading players in antibiotic research, a field that has been neglected by larger pharma companies but is now a growing ... He said: “I am confident that we will drive excellence in the research,

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest from PMHub

  • Antibiotic resistance: The silent pandemic

    Available at: https://www.sgu.edu/blog/medical/what-is-antibiotic-resistance/. Accessed November 2019. UK Research and Innovation. An introduction to antimicrobial resistance. ... Available at:

  • Adelphi Research UK Welcomes Six New Starters

    During her time at Leeds she spent a year in a research laboratory. ... She has carried out exchange programmes in China and Hong Kong and has also completed two research internships in novel antibiotic discovery.

More from PMHub
Approximately 0 fully matching, plus 2 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Porterhouse Medical Group

The Porterhouse Medical Group provides powerful, insight-driven, healthcare communication services to the pharmaceutical industry across the globe, with a focus...

Latest intelligence

How can we strike the right balance between familiarity and innovation when it comes to data presentation?
Following our webinar in March, Getting MedComms right: navigating the age of the amateur expert, we’re taking the time to respond to questions we were unable to answer during the...
Deep 6 AI: the smart software breathing new life into clinical trials
Fishawack Health interviews Wout Brusselaers, the Deep 6 AI CEO using artificial intelligence to solve one of the greatest barriers stagnating healthcare innovation—clinical trial recruitment and retention....
COVID-proof: How Teams are Creating Launch Intensity thru Adversity
Now that the game has changed, how are marketers shifting their launch behaviour? We've identified 5 common observations from effective teams....